Navigation Links
Transgenomic Reports Second Quarter Financial Results
Date:8/11/2011

y technologies and tests we have developed internally or in-licensed, expanding our menu. In particular, we have substantially increased our footprint in the molecular diagnostics laboratory market through our acquisition of the FAMILION laboratory testing business.  This acquisition brings us historic annual revenues of approximately $13.0 million and a much larger presence both with insurers and patients. This acquisition also provides us access to higher throughput technologies and an expert staff to aid us as we continue growing our reference laboratory business as well as consolidation opportunities already achieved in laboratory operations, billing and customer service functions.

In our Pharmacogenomic Services Lab, we continue to perform cancer pathway gene mutation analysis for a number of pharmaceutical companies: both for pre-clinical drug discovery projects and phase II and III clinical trials.  We can now analyze a patient's blood serum rather than a tumor to detect DNA mutations, using our recently licensed ultra-sensitive DNA mutation detection technology, termed "COLD-PCR", and a significant improvement to COLD-PCR termed "Ice COLD-PCR". This is a significant achievement, and we believe it should lead to faster growth of our pharmacogenomics research services as pharmaceutical companies adopt this novel approach for both drug and disease research.

In addition to Ice COLD-PCR, which offers sensitivity improvements as much as 1,000 times higher than routine DNA testing technology, we have recently discovered a technique to further improve mutation detection sensitivity of standard Sanger sequencing. We have termed this new discovery "BLOCker-Sequencing" and we are combining this new discovery with our Ice COLD-PCR program to bring what we believe to be the most accurate and sensitive mutation detection technology available in the market today.

We believe that this combination of technologies offers us the ability
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011
2. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
3. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
4. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
5. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
6. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
7. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
8. Transgenomic Reports Third Quarter Financial Results
9. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
10. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... Germany, 21-25 June, featured highlights including two Nobel Laureates who presented during an ... enhance the resolution of microscopes. , SPIE Optical Metrology (SPIE OM) ...
(Date:7/7/2015)... , July 7, 2015 ... - Gene Therapy Market Analysis" report is an ... gene therapy field. Using detailed company data, deal ... provides an in-depth analysis of the current and ... The report discusses the key factors shaping and ...
(Date:7/7/2015)... 7, 2015 Genes in Space, a ... is landing at New England Biolabs® (NEB®) along ... of scientific exploration and celebration, on Thursday, July ... between Boeing®, The Center for Advancement of Science ... students to design an experiment to solve a ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... demand for biologic are some of the factors driving the pharmaceutical contract manufacturing ... manufacturers, as well as contract manufacturing organizations (CMOs), are driving market growth. Drug ...
Breaking Biology Technology:Light-Based Technologies at Work: ‘Seeing’ Through Walls, Monitoring Cancer Treatments and Air Pollution, Preserving Artworks -- and Much More 2Light-Based Technologies at Work: ‘Seeing’ Through Walls, Monitoring Cancer Treatments and Air Pollution, Preserving Artworks -- and Much More 3Light-Based Technologies at Work: ‘Seeing’ Through Walls, Monitoring Cancer Treatments and Air Pollution, Preserving Artworks -- and Much More 4Light-Based Technologies at Work: ‘Seeing’ Through Walls, Monitoring Cancer Treatments and Air Pollution, Preserving Artworks -- and Much More 5PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis 2Genes in Space finalists attend laboratory workshop and celebration at New England Biolabs' headquarters 2More Drug Companies Increasing Outsourcing Budgets; CMO Partners Spring Up as Market Thrives, According to BCC Research 2More Drug Companies Increasing Outsourcing Budgets; CMO Partners Spring Up as Market Thrives, According to BCC Research 3
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... drug discovery and life sciences research for personalized medicine, ... meeting on May 17th and 18th.  This annual event ... diagnostics to discuss the technologies and discoveries that are ...
... ROCKVILLE, Md., May 5, 2011 Vanda Pharmaceuticals Inc. ... focused on the development and commercialization of products for ... results for the first quarter ended March 31, 2011. ... progress we have made to date in 2011," said ...
... PASADENA, Calif., May 4, 2011 Highlights ... from Operations ("FFO") Per Share (Diluted) Attributable to Alexandria Real ... 2011 Losses on Early Extinguishment of Debt, Up 6% Compared ... First Quarter 2011 Earnings Per Share (Diluted) Attributable to ...
Cached Biology Technology:Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 2Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 3Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 4Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 5Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 6Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 7Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 10Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 11Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 12Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 13Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 15Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 16
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... new study in mice, a scientific collaboration centered at ... signaling breakdown in Angelman syndrome, a disorder that affects ... seizures, and other problems. With the new understanding, the ... works to restore neural functions impaired by the disease. ...
... FRANCISCO February 12, 2013 New findings from a ... predict whether a person is likely to develop age-related macular ... than nine million Americans, these genes do not predict how ... most widely used to treat the "wet" form of AMD. ...
... New Geology science posted online ahead of ... several sites in the U.S., as well as work ... southeastern Pacific, South Africa, and Mars. Tectonics, flooding, carbon ... Brief highlights follow. Papers cover , 1. ...
Cached Biology News:Study in mice yields Angelman advance 2Study in mice yields Angelman advance 3Study in mice yields Angelman advance 4Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments 2The Geological Society of America Journal Geology: Dynamic geoscience 2The Geological Society of America Journal Geology: Dynamic geoscience 3The Geological Society of America Journal Geology: Dynamic geoscience 4The Geological Society of America Journal Geology: Dynamic geoscience 5The Geological Society of America Journal Geology: Dynamic geoscience 6The Geological Society of America Journal Geology: Dynamic geoscience 7The Geological Society of America Journal Geology: Dynamic geoscience 8The Geological Society of America Journal Geology: Dynamic geoscience 9The Geological Society of America Journal Geology: Dynamic geoscience 10The Geological Society of America Journal Geology: Dynamic geoscience 11The Geological Society of America Journal Geology: Dynamic geoscience 12The Geological Society of America Journal Geology: Dynamic geoscience 13The Geological Society of America Journal Geology: Dynamic geoscience 14The Geological Society of America Journal Geology: Dynamic geoscience 15
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Trypsin (Pig Pancreas) (TPCK Treated, Highly Purified)...
Homo sapiens palladin...
Biology Products: